Ellington Management Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ellington Management Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-17,300	Closed	-$102K	–	799
2019 Q3	$102K	Buy	+17,300	New	+$184K	0.02%	555
2017 Q2	–	Sell	-19,000	Closed	-$324K	–	966
2017 Q1	$324K	Buy	+19,000	New	+$228K	0.01%	439

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Ellington Management Group's CNCE Position: Q4 2019 in Review

Ellington Management Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 17,300 shares — an estimated $102K sold.

Ellington Management Group first reported a position in CNCE in Q1 2017 and held it in 2 quarters. The position peaked at $324K in Q1 2017. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

Ellington Management Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Ellington Management Group sold 17,300 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $102K.
Ellington Management Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
Ellington Management Group's Concert Pharmaceuticals, Inc. position peaked at $324K in Q1 2017.
77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.